Posts by John

Discover the latest in pharma: RevMed and BeOne form a strategic Asian clinical trial partnership, while MoonLake celebrates a successful Phase 3 result.

Novo Nordisk removes a Catalent site from its FDA SMA drug filing to ensure regulatory success and streamline the path to market for its therapy.

Neurocrine Biosciences has launched Phase 1 trials for NBI-P'1968, a promising triple agonist targeting obesity. Learn about this new weight-loss approach.

NanoViricides receives Phase II approval for NV-387 oral gummies to treat Ebola. Learn how this innovative antiviral could reshape outbreak response.

Tenax Therapeutics’ heart failure drug, levosimendan, failed its pivotal Phase 3 trial. See the impact on PH-HFpEF treatment and the latest trial data.

WHO pushes for a Phase III trial of the Ervebo vaccine to combat the Bundibugyo Ebola outbreak. Discover the latest updates on this critical health move.

AbCellera’s ABCL635 shows promise in Phase 2 trials, significantly reducing hot flash frequency and severity with a favorable safety profile.

New Phase 2 data confirms ABCL635 significantly reduces hot flash severity and frequency, offering a promising non-hormonal breakthrough for patient care.

Veru reports Q3 fiscal results and provides a critical update on the Phase 2b PLATEAU trial for enobosarm, a candidate targeting muscle-wasting conditions.

Explore the rapid rise of radiopharmaceuticals, the clinical promise of targeted cancer therapy, and the critical safety hurdles facing this field.